Short answer

There is no ASEAN-wide approval: the ASEAN Medical Device Directive harmonises risk classes A to D and the CSDT dossier format, but each country registers devices separately. An EU MDR certificate changes the route. Singapore’s HSA accepts it as a reference approval for its abridged route, and Malaysia’s MDA for conformity assessment by way of verification. HSA or MDA approvals then support the Philippine abridged process and the Malaysia–Thailand reliance programme, while Indonesia and Vietnam treat foreign approvals as supporting evidence in a national registration. Most EU-certified companies start with Singapore and Malaysia in parallel, and every market needs its own local party, such as a registrant, authorised representative or importer.

What EU MDR certification does — and does not — do in ASEAN

There is no ASEAN-wide approval. The ASEAN Agreement on Medical Device Directive (AMDD, signed in Bangkok on 21 November 2014, in force since 1 January 2015) harmonises the risk classes (A to D) and the Common Submission Dossier Template (CSDT, Annex 4), but it does not create mutual recognition: a device has to be registered with the regulator of each Member State where it is placed on the market.

What your EU MDR certificate changes is the route. Singapore's HSA lists EU Notified Body certificates among its recognised reference approvals, which opens its abridged route and, where the extra conditions are met, its expedited or immediate routes. Malaysia's MDA accepts EU MDR certificates for conformity assessment by way of verification. Thailand and the Philippines operate reliance routes based on approvals from other ASEAN regulators. In Indonesia and Vietnam, foreign approvals are supporting evidence in a national registration.

The ASEAN strategy principle: for an EU MDR certified SaMD, Singapore and Malaysia are usually the natural first pair — both accept your EU certificate as a reference, and since 2025–2026 each also relies on the other's approvals. An HSA or MDA approval then supports the Philippine abridged process and the Malaysia–Thailand reliance programme. It does not unlock the other markets automatically.

Market 1: Singapore (HSA)

HSA regulates software under its general medical device framework, with software-specific expectations in GL-04 Revision 4 — Regulatory Guidelines for Software Medical Devices including Machine Learning-Enabled Medical Devices – A Life Cycle Approach (effective 31 December 2025). It covers the software lifecycle, cybersecurity (including operating system end-of-support), machine-learning-enabled devices and the Change Management Program for SaMD. The details are in our Singapore HSA SaMD registration guide.

With an EU MDR certificate covering the same labelled use, a Class B, C or D device normally qualifies for the abridged route. HSA's published target turnaround times — in working days, excluding the time you take to answer queries — are 100 (Class B), 160 (Class C) and 220 (Class D) on the abridged route, against 160, 220 and 310 on the full route. Expedited and immediate routes exist for devices that meet additional conditions (for example, approval from two reference agencies, or at least three years of marketing in reference jurisdictions), and standalone medical mobile applications in Class B and C have their own immediate route.

Singapore-specific work beyond the EU file: a dossier in CSDT format (HSA guidance GN-17), HSA's authorisation and declaration templates (GN-15 annexes), a Singapore registrant to hold the registration, and HSA-licensed dealers where software is imported or supplied wholesale — GL-04 notes that a local entity providing cloud-based access to software needs a wholesaler's licence.

Market 2: Malaysia (MDA)

Malaysia regulates devices under the Medical Device Act 2012 (Act 737). Class B, C and D devices that already hold an approval from a recognised authority can use conformity assessment by way of verification: an MDA-registered Conformity Assessment Body (CAB) verifies the manufacturer's evidence instead of performing a full conformity assessment, and the application is then submitted to MDA through MeDC@St (MDA/GD/0070, second edition, October 2025). MDA's list of recognised approvals includes EU Notified Body certificates under the MDR, as well as US FDA, Health Canada, TGA, Japan, UK MHRA, Singapore HSA (SMDR listing) and Thai FDA approvals.

So an EU MDR certified SaMD does not need a Singapore registration to use the verification route. MDA's guidance gives an approximate CAB turnaround of 1.5 months for verification and 30 working days for MDA's decision on a complete Class B–D application. For devices relying on an HSA registration, MDA moved the HSA–MDA programme to full implementation from 1 March 2026.

Malaysia-specific requirements: an Authorised Representative licensed and domiciled in Malaysia, a Declaration of Conformity in the format set by the Medical Device Regulations 2012, labelling under MDA/GD/0026 (English for professional-use devices, Bahasa Malaysia for home-use devices) and the Malaysian registration number on labelling within six months of registration. See our Malaysia MDA registration guide.

Market 3: Thailand (Thai FDA)

Thai FDA regulates devices under the Medical Device Act B.E. 2551 (2008), as amended by the Medical Device Act (No. 2) B.E. 2562 (2019). Devices fall into four risk classes: Class 1 is the lowest risk, Classes 2 and 3 are registered by detailed notification, and Class 4 by licence. Thai FDA has also published SaMD-specific registration guidance; industry sources date it to May 2024, but we could not open the Thai FDA page to confirm its content, so check the current version before you rely on any checklist.

The confirmed reliance route runs through Malaysia: MDA and Thai FDA piloted a reliance programme from 1 February to 30 April 2026 and announced full implementation on 1 May 2026 for Class B, C and D devices. Devices approved by MDA can skip Thai FDA's external expert evaluation after a full CSDT submission; devices approved by Thai FDA can use MDA's verification route. More in our Thailand FDA SaMD guide.

Market 4: Philippines (FDA)

The Philippine FDA (Center for Device Regulation, Radiation Health and Research) registers medical devices under Administrative Order No. 2018-0002, which implements the ASEAN harmonised technical requirements. FDA Circular No. 2022-008 provides abridged processing for Class B, C and D devices already approved by the regulator of any ASEAN Member State: the dossier must be identical to the one that regulator approved, the technical documentation is not re-reviewed (labelling is), and the stated processing time is 30 working days from proof of payment. IVDs and refurbished devices are excluded.

An EU certificate on its own does not trigger this route — an approval from an ASEAN regulator such as HSA or MDA does. The application is filed by a local establishment holding an FDA License to Operate, typically your Philippine importer or distributor.

Market 5: Indonesia (Ministry of Health)

Indonesia's Ministry of Health issues the marketing authorisation (izin edar) for medical devices. Its published guidelines classify devices into Classes A to D and, for imported devices, require an Indonesian distributor holding a medical device distribution licence, a letter of authorisation from the manufacturer and a certificate of free sale. We did not find an abridged or reliance route based on foreign approvals in the Ministry's evaluation guideline (November 2020); EU and ISO 13485 certificates serve as supporting evidence. The legal framework has been reorganised since, so confirm current requirements on the Ministry's registration portal before planning.

Market 6: Vietnam (Ministry of Health)

Vietnam's Ministry of Health regulates medical devices under Decree 98/2021/ND-CP, as amended. We could not confirm on an official Vietnamese source a dedicated expedited route for devices registered with HSA, so treat Vietnam as a national registration and confirm the current rules — including any recognition of foreign approvals and translation requirements — with a local registration partner before committing to dates.

Recommended sequencing

Step 1 — Singapore and Malaysia, in parallel. Both accept your EU MDR certificate as a reference, and Malaysia's verification route does not depend on a Singapore registration. Appoint the Singapore registrant and the Malaysian Authorised Representative early; they gate both submissions. This is the step we support in our Singapore HSA and Malaysia MDA registration service for EU-certified software.

Step 2 — Philippines and Thailand. With an HSA or MDA approval in hand, the Philippine abridged processing and the MDA–Thai FDA reliance programme become available. Reuse the CSDT exactly as approved — both routes depend on the dossier being the same.

Step 3 — Indonesia and Vietnam. Plan these as national registrations with local partners, reusing the CSDT content but expecting local formats and translations.

Regulators publish target review times for some of these routes, but overall project duration depends on local partner set-up, dossier quality and query rounds. We therefore do not quote a fixed regional calendar — build the plan market by market.

Official sources & references